The investigators hypothesize that R-roscovitine will suppress pituitary corticotroph tumor
ACTH production and normalize urinary free cortisol levels in patients with Cushing disease.
To date, R-roscovitine has been evaluated in several Phase I and II studies and has shown
early signs of anti-cancer activity in approximately 240 patients.
Phase:
Phase 2
Details
Lead Sponsor:
Shlomo Melmed, MD
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)